Though the longstanding treatment focus for patients with Alzheimer’s disease (AD) has been on amyloid-beta and tau protein accumulation in the brain, evidence continues to spotlight neuroinflammation as a key contributor to AD progression. The presence of toxic amyloid-beta species along with excess and chronic systemic inflammatory responses fuels a cycle of amyloid-beta plaque and tau tangle accumulation along with activation of microglia in the brain. Multidirectional relationships among these and other processes chronically promote the damage and neurodegeneration characteristic of AD. Clinicians and multidisciplinary care teams must be appraised on the rapidly maturing science of neuroinflammation as a disease-modifying target for AD to understand emerging treatments of value.
In the second activity of this three-part CME Outfitters Snack series, expert faculty will guide learners through evaluating the role of neuroinflammation in the pathology and progression from mild cognitive impairment (MCI) to AD and dementia.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Novo Nordisk, Inc.
Primary Audience: Physicians, nurse practitioners (NPs), and physician associates (PAs) in the neurology, geriatric, and psychiatry settings
Secondary Audience: PCPs and supporting HCPs who evaluate or refer patients with MCI or manage patients with AD
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 0.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-032-H01-P).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 06/21/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Atri reports the following financial relationships:
Advisory Board: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; and Roche/Genentech, Inc.
Consultant: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; Prothena; and Roche/Genentech, Inc.
Grants: (Institutional research grant/contract funding): Arizona Department of Health Services; Foundation for National Institutes of Health (FNIH); Gates Ventures; National Institute on Aging (NIA/NIH; and Washington University St. Louis (as Project Arm Leader for DIAN-TU)
Research Support (Institutional research support or grants for observational or biomarker studies or clinical trials): Alzheimer’s Disease Consortia – Coordinating research institutes or government funding (Alzheimer’s Clinical Trials Consortium (ACTC); Alzheimer’s Disease Cooperative Study (ADCS); Alzheimer’s Therapeutic Research Institute; (ATRI); National Institutes of Health (NIH); Athira Pharma, Inc.; Alzheon, Inc.; Biohaven (with ADCS); Eisai Inc. (with ATRI/ACTC); Global Alzheimer’s Platform Foundation; Indiana University (observational cohort); Johns Hopkins (clinical trial); Lilly (with ACTC/NIH); PEACE-AD Study (with ADCS); Vivoryon (with ADCS)
Dr. Edison reports the following financial relationships:
Consultant: Biohaven and Roche
Grants: Novo Nordisk
Research Support: Amyloid PET tracers from Life Molecular Imaging; Eli Lilly and Company; and GE HealthCare
Speakers Bureau: GSK
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Erin Spencer, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
SN-233-062124-68
